Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ancient herbs speed up heart surgery recovery?

NCT ID NCT07781436

Disease control Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial tests whether a traditional Chinese herbal formula, Fuzheng Yangxin, can help people recover better after coronary artery bypass grafting (CABG), a common heart surgery. The study includes 230 patients who have the surgery and show signs of a specific imbalance (qi-yin deficiency) afterward. Half will receive the herbal granules for 7 days after surgery, alongside standard care, while the other half gets standard care alone. Researchers will measure chest pain, physical limitations, hospital stay length, and heart-related complications to see if the herbs improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fuzheng Yangxin Formula granules, a traditional Chinese herbal mixture
What this could lead to
If effective, this herbal formula could become a standard add-on to help heart bypass patients recover faster, with less chest pain and a shorter hospital stay.
What could go wrong
This is a single, mid-sized trial, and herbal formulas can vary in quality and effects. It may not show a clear benefit, and some patients could have side effects or interactions with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 230 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -Patients who have undergone coronary artery bypass grafting (CABG) and present with postoperative qi-yin deficiency syndrome. Exclusion Criteria: * Patients with hypersensitivity to any components of Fuzheng Yangxin Formula granules. * Patients with fever or common cold after surgery. * Patients with severe postoperative liver and kidney dysfunction. * Patients who receive concurrent valve surgery or other intracardiac operations * Patients with end-stage malignant tumors * Patients with uncontrolled infection or bleeding * Patients with progressive degenerative systemic diseases, such as severe trauma, multiple organ failure and other severe impairment of vital organ function including severely damaged liver function * Patients with severe heart failure or cardiogenic shock who cannot tolerate treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CABG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CABG Cad - coronary artery disease ERAS Medicine, chinese traditional

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University 3rd hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.